Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
05 juin 2024 06h45 HE
|
MannKind
INHALE-3 STUDY RESULTS TO BE PRESENTED DURING A 90-MINUTE SYMPOSIUM ON SATURDAY, JUNE 22 AT THE AMERICAN DIABETES ASSOCIATION’S 84TH SCIENTIFIC SESSIONS
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
29 mai 2024 08h45 HE
|
MannKind
MANNKIND TO ESTABLISH BOSTON-AREA RESEARCH & DEVELOPMENT FOOTHOLD AND EXPAND PORTFOLIO OF DRY POWDER INHALATION TECHNOLOGY IN TRANSACTION WITH PULMATRIX
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
08 mai 2024 16h18 HE
|
MannKind
1Q 2024 Total revenues of $66M; +63% vs. 1Q 20231Q 2024 Net income of $11M; Non-GAAP net income of $15M$304M of cash and cash equivalents and investments at March 31, 2024In early April, repaid Midcap...
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
06 mai 2024 06h05 HE
|
MannKind
MANNKIND RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR CLOFAZIMINE INHALATION SUSPENSION FOR THE TREATMENT OF SERIOUS LUNG DISEASE
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
01 mai 2024 16h00 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2024 first quarter financial results and its management will host a...
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
30 avr. 2024 06h05 HE
|
MannKind
MannKind announced it will proceed with a Phase 1 study of nintedanib DPI (MNKD-201) for pulmonary fibrotic diseases including IPF.
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
29 avr. 2024 06h05 HE
|
MannKind
MANNKIND ANNOUNCES IND CLEARANCE FROM U.S. FDA TO START PHASE 3 STUDY OF CLOFAZIMINE INHALATION SUSPENSION FOR NTM LUNG DISEASE
MannKind Repays Certain Debt Obligations
03 avr. 2024 06h00 HE
|
MannKind
Credit and security agreement with MidCap Financial Trust repaid in full for approximately $31.6 millionConvertible note issued to Mann Group LLC repaid in exchange for 1.5 million shares of common...
MannKind Announces CFO Transition
26 mars 2024 16h05 HE
|
MannKind
MANNKIND ANNOUNCES CFO TRANSITION
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
11 mars 2024 06h05 HE
|
MannKind
INHALE-3 STUDY’S INITIAL MEAL CHALLENGE RESULTS COMPARING AFREZZA® HEAD-TO-HEAD WITH MULTIPLE DAILY INJECTIONS (MDI) AND INSULIN PUMPS